Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Andrew Elbardissi
AddedMar 31, 2024
UpdatedMay 31, 2026
Andrew Elbardissi

Andrew Elbardissi

Board Member, Longitude Capital

CrunchbaseLinkedIn

Andrew Elbardissi's Career

Longitude Capital
Longitude Capital

Menlo Park, CA, US

Board Member· Board
Acutus Medical
Acutus Medical

Carlsbad, CA, US

Board Member· Board
Encodia
Encodia

San Diego, CA, US

Board Member· Board
NeoChord
NeoChord

St. Louis Park, MN, US

Board Member· Board
InCarda Therapeutics
InCarda Therapeutics

Newark, CA, US

Board Member· Board
Aurion Biotech
Aurion Biotech

Seattle, WA, US

Board Member· Board
Epic Sciences
Epic Sciences

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Andrew Elbardissi's Career

Longitude Capital
Longitude Capital
Investment FirmInvestment Firm452006Menlo Park, CA, US
Board Member· Board

Leadership at Longitude Capital

Andrew CleelandAndrew CleelandBoard Member
David HirschDavid HirschCo-Founder
Lisa SuennenLisa SuennenBoard Member
Patrick EnrightPatrick EnrightCo-Founder
Juliet Tammenoms BakkerJuliet Tammenoms BakkerCo-Founder
Marc-Henri GallettiMarc-Henri GallettiCo-Founder

Similar to Longitude Capital

Longwood FundLongwood FundBoston, MA, USest. 2010Longwood FundBoston, MA, US · est. 2010

Longwood Fund Management: A US-based venture capital firm specializing in healthcare and biotech investments.

Investment Firm20
Longevity Vision FundLongevity Vision FundNew York City, NY, USest. 2019Longevity Vision FundNew York City, NY, US · est. 2019

LVF: A venture capital fund investing in disruptive healthcare technologies for longer, healthier lives.

Investment Firm15
Longley CapitalLongley CapitalSan Diego, CA, USest. 2019Longley CapitalSan Diego, CA, US · est. 2019

Longley Capital: A tech-focused investment firm, nurturing visionary ideas to boost enterprise value.

Investment Firm2
The Longevity FundThe Longevity FundSan Francisco, CA, USest. 2011The Longevity FundSan Francisco, CA, US · est. 2011

Longevity Fund: Investing in human longevity through innovative investment solutions.

Investment Firm2
Acutus Medical
Acutus Medical

Carlsbad, CA, US

Board Member· Board
Encodia
Encodia
Series C$75M692015San Diego, CA, US
Board Member· Board

Leadership at Encodia

Mark CheeMark CheeFounder

Similar to Encodia

CodettaCodettaDurham, NC, USBiotechnology, Platformest. 2021CodettaDurham, NC, US · est. 2021

Codetta Bio offers a multi-omic analysis platform for accelerated R&D of next-gen therapies, enhancing patient care.

Seed · $17M35
Range BiotechnologiesRange BiotechnologiesSan Carlos, CA, USProteomics Toolsest. 2021Range BiotechnologiesSan Carlos, CA, US · est. 2021

San Carlos-based Range Biotechnologies develops proteomics tools for personalized health insights and disease study.

Seed · $5.2M6
Proteios TechnologyProteios TechnologySeattle, WA, USBiopharmaceuticals, Kitsest. 2015Proteios TechnologySeattle, WA, US · est. 2015

Proteios Technology: Your affordable gateway to quality biopharmaceuticals.

Pre-Seed · $1.2M5
ProteoWiseProteoWiseBranford, CT, USProteomics Solutionsest. 2018ProteoWiseBranford, CT, US · est. 2018

ProteoWise: Revolutionizing proteomics with high-throughput, cost-effective solutions from Yale scientists.

Seed · $8.9M6
NeoChord
NeoChord
Seed$89.9M242009St. Louis Park, MN, US
Board Member· Board

Leadership at NeoChord

Mudit K JainMudit K JainBoard Member
David ChungDavid ChungCEO
Kyle SalyersKyle SalyersBoard Member
Nicole J WalkerNicole J WalkerBoard Member
Casey TanseyCasey TanseyBoard Member
John SeabergJohn SeabergFounder

Similar to NeoChord

Cardiac DimensionsCardiac DimensionsKirkland, WA, USMedical Devicesest. 2001Cardiac DimensionsKirkland, WA, US · est. 2001

US-based Cardiac Dimensions develops global medical devices for heart failure and mitral valve treatment.

Public · $209.7M62
Nectero MedicalNectero MedicalDover, DE, USMedical Devicesest. 2017Nectero MedicalDover, DE, US · est. 2017

Nectero Medical: Innovating treatments to stabilize and prevent abdominal aortic aneurysms.

Series C · $19.5M14
NeocisNeocisMiami, FL, USSurgical Robotsest. 2009NeocisMiami, FL, US · est. 2009

Neocis: Revolutionizing dental surgery with advanced, robot-assisted implant technology.

Series D · $183.1M175
NicoNicoIndianapolis, IN, USMedical Devicesest. 2007NicoIndianapolis, IN, US · est. 2007

NICO Corp: Global provider of innovative medical devices for minimally invasive neuro and spinal surgeries.

Series B · $68.1M104
InCarda Therapeutics
InCarda Therapeutics
Series A$86.4M102009Newark, CA, US
Board Member· Board

Leadership at InCarda Therapeutics

George BickerstaffGeorge BickerstaffBoard Member
Gregory M. MarcusGregory M. MarcusCo-Founder
Adam FreundAdam FreundCo-Founder
Narsi RangachariNarsi RangachariCo-Founder
Robert LisickiRobert LisickiCEO
Carlos SchulerCarlos SchulerCo-Founder

Similar to InCarda Therapeutics

Cardeas PharmaCardeas PharmaSeattle, WA, USAntibiotics, Pharmaceuticalsest. 2010Cardeas PharmaSeattle, WA, US · est. 2010

Cardeas Pharma: Specializing in developing inhaled antibiotics for respiratory infections.

Series B · $80M30
BioCardiaBioCardiaSan Carlos, CA, USMedical Devices, Therapeuticsest. 1999BioCardiaSan Carlos, CA, US · est. 1999

BioCardia, a San Carlos-based medical firm, develops innovative regenerative therapies for critical cardiovascular diseases.

Public · $41.3M28
Respira TherapeuticsRespira TherapeuticsAlbuquerque, NM, USDrug Delivery, Inhalationest. 2010Respira TherapeuticsAlbuquerque, NM, US · est. 2010

Respira: A drug delivery tech company specializing in efficient dry powder inhaler technologies.

Series B · $5.1M9
Cardurion PharmaceuticalsCardurion PharmaceuticalsBurlington, MA, USTherapeuticsest. 2017Cardurion PharmaceuticalsBurlington, MA, US · est. 2017

Boston-based biotech firm specializing in next-gen therapeutics for heart diseases.

Series B · $343.1M42
Aurion Biotech
Aurion Biotech
Late Stage Private$120M552021Seattle, WA, US
Board Member· Board

Leadership at Aurion Biotech

Tom FrinziTom FrinziBoard Member
Greg KunstGreg KunstBoard Member

Similar to Aurion Biotech

Imagen BiotechImagen BiotechNew York City, NY, USTherapeuticsest. 2011Imagen BiotechNew York City, NY, US · est. 2011

Imagen Biotech: Pioneering solutions for blinding diseases through innovative therapeutics.

Series A · $40M30
Qlaris BioQlaris BioWellesley, MA, USTherapeuticsest. 2019Qlaris BioWellesley, MA, US · est. 2019

Therapeutics firm focusing on high-need areas in debilitating eye diseases.

Series A · $25M9
Aureka BiotechnologiesAureka BiotechnologiesLaguna Hills, CA, USDrug Discoveryest. 2023Aureka BiotechnologiesLaguna Hills, CA, US · est. 2023

Aureka Biotechnologies: Pioneering biotech firm democratizing pharma to conquer sickness.

Seed · $10M30
Curie.BioCurie.BioBoston, MA, USDrug Developmentest. 2022Curie.BioBoston, MA, US · est. 2022

Curie.Bio: A seed-stage venture firm specializing in drug-focused services for founders.

Series B26
Epic Sciences
Epic Sciences
Series G$219.5M1142008San Diego, CA, US
Board Member· Board

Leadership at Epic Sciences

Evgeny ZaytsevEvgeny ZaytsevBoard Member
Greg LucierGreg LucierBoard Member
Kim KamdarKim KamdarBoard Member
Richard EglenRichard EglenBoard Member
James RothmanJames RothmanBoard Member
Murali PrahaladMurali PrahaladBoard Member

Similar to Epic Sciences

Epi OneEpi OneNew York City, NY, USCancer Diagnosticsest. 2016Epi OneNew York City, NY, US · est. 2016

Revolutionary cancer diagnosis platform for early prognosis, detection, and drug response.

Series B · $22.9M36
EpinomaEpinomaSan Francisco, CA, USCancer Diagnosticsest. 2020EpinomaSan Francisco, CA, US · est. 2020

Innovative diagnostics company using multi-omics for cancer monitoring. Founded in 2020, based in San Francisco.

Pre-Seed · $125k6
OnCirc DiagnosticsOnCirc DiagnosticsBeverly Hills, CA, USCancer Diagnosticsest. 2009OnCirc DiagnosticsBeverly Hills, CA, US · est. 2009

Innovative cancer diagnostics biotech in Beverly Hills.

Pre-Seed · $500k30
Exact SciencesExact SciencesMadison, WI, USCancer Diagnosticsest. 1995Exact SciencesMadison, WI, US · est. 1995

Exact Sciences Corp., a US-based firm, develops non-invasive tests for early colorectal cancer detection.

Public · $2.1B6.4k

Andrew Elbardissi's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Andrew Elbardissi

Bill SlatteryBill SlatteryBoard Member · Appello PharmaceuticalsHowie FurstHowie FurstBoard Member · Appello PharmaceuticalsLeslie HenshawLeslie HenshawBoard Member · Advantia HealthEddie KangEddie KangBoard Member · BoulevardJeremiah DalyJeremiah DalyCo-Founder · ElephantAndy ChenAndy ChenBoard Member · Persona